Companies › Marker Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MT-601 Multi-antigen specific CD4+ and CD8+ T cells | – | Phase 1 | Non-Hodgkin Lymphoma, Adult | Feb 2028 |
| MT-401-OTS off-the-shelf allogeneic T-cell therapy | – | Phase 1 | Acute Myeloid Leukemia, in Relapse | Sep 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05798897 | MT-601 | Phase 1 | Non-Hodgkin Lymphoma, Adult | Oncology | Feb 2028 |
| NCT06552416 | MT-401-OTS | Phase 1 | Acute Myeloid Leukemia, in Relapse | Oncology | Sep 2029 |
Cash of $11m on 2026-06-30; operating cash outflow about $10m a year; runway about 13 months at that burn, to Aug 2027
Press releases filed as 8-K in the last year:
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.